prikaz prve stranice dokumenta Cortisol in schizophrenia: no association with tobacco smoking, clinical symptoms or antipsychotic medication
  Preuzmi
PDF 419.87 KB
Znanstveni rad - Izvorni znanstveni rad
Cortisol in schizophrenia: no association with tobacco smoking, clinical symptoms or antipsychotic medication
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 77 (2017); 228-235. https://doi.org/10.1016/j.pnpbp.2017.04.032
Nedić Erjavec, Gordana; Uzun, Suzana; Nikolac Perković, Matea; Kozumplik, Oliver; Švob Štrac, Dubravka; Mimica, Ninoslav; Hirasawa-Fujita, Mika; Domino, Edward F.; Pivac, Nela

Citirajte ovaj rad

Nedić Erjavec, G., Uzun, S., Nikolac Perković, M., Kozumplik, O., Švob Štrac, D., Mimica, N. ... Pivac, N. (2017). Cortisol in schizophrenia: no association with tobacco smoking, clinical symptoms or antipsychotic medication. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 77., 228-235. doi: 10.1016/j.pnpbp.2017.04.032

Nedić Erjavec, Gordana, et al. "Cortisol in schizophrenia: no association with tobacco smoking, clinical symptoms or antipsychotic medication." Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 77, 2017, str. 228-235. https://doi.org/10.1016/j.pnpbp.2017.04.032

Nedić Erjavec, Gordana, Suzana Uzun, Matea Nikolac Perković, Oliver Kozumplik, Dubravka Švob Štrac, Ninoslav Mimica, Mika Hirasawa Fujita, Edward F. Domino i Nela Pivac. "Cortisol in schizophrenia: no association with tobacco smoking, clinical symptoms or antipsychotic medication." Progress in Neuro-Psychopharmacology and Biological Psychiatry 77 (2017): 228-235. https://doi.org/10.1016/j.pnpbp.2017.04.032

Nedić Erjavec, G., et al. (2017) 'Cortisol in schizophrenia: no association with tobacco smoking, clinical symptoms or antipsychotic medication', Progress in Neuro-Psychopharmacology and Biological Psychiatry, 77, str. 228-235. doi: 10.1016/j.pnpbp.2017.04.032

Nedić Erjavec G, Uzun S, Nikolac Perković M, Kozumplik O, Švob Štrac D, Mimica N, i sur.. Cortisol in schizophrenia: no association with tobacco smoking, clinical symptoms or antipsychotic medication. Progress in Neuro-Psychopharmacology and Biological Psychiatry [Internet]. 07.2017. [pristupljeno 12.04.2024.];77:228-235. doi: 10.1016/j.pnpbp.2017.04.032

G. Nedić Erjavec, et al., "Cortisol in schizophrenia: no association with tobacco smoking, clinical symptoms or antipsychotic medication", Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 77, str. 228-235, Srpanj 2017. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:238952. [Citirano: 12.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:238952
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Cortisol in schizophrenia: no association with tobacco smoking, clinical symptoms or antipsychotic medication
AutorGordana Nedić Erjavec
AutorSuzana Uzun
AutorMatea Nikolac Perković
AutorOliver Kozumplik
AutorDubravka Švob Štrac
AutorNinoslav Mimica
AutorMika Hirasawa-Fujita
AutorEdward F. Domino
AutorNela Pivac
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Cigarette smoking is associated with higher cortisol levels in healthy subjects. In schizophrenia this relationship is not clear. There are divergent results on the association between cortisol with smoking, clinical symptoms and medication in schizophrenia. This study evaluated this association in 196 Caucasian inpatients with schizophrenia (51.30±26.68years old), subdivided into 123 smokers and 73 non-smokers. Basal salivary cortisol levels were measured twice, at 08.00 and 09.00AM, 90-120min after awakening. The effect of smoking on cortisol was evaluated according to current smoking status, the number of cigarettes/day and the nicotine addiction intensity. The influence of clinical symptoms and/or antipsychotic medication on cortisol was determined using the Positive and Negative Syndrome Scale (PANSS), and chlorpromazine equivalent doses. Non-smokers were older, received lower doses of antipsychotics, had higher PANSS scores, and had longer duration of illness than smokers. Salivary cortisol was similar in schizophrenic patients subdivided according to the smoking status, the number of cigarettes/day and nicotine addiction intensity. No significant correlation was found between salivary cortisol and PANSS scores, chlorpromazine equivalent doses, age of onset or the duration of illness. The findings revealed no association between salivary cortisol and smoking, nicotine addiction intensity, or clinical symptoms. Our preliminary data showed no correlation between salivary cortisol and chlorpromazine equivalent doses and/or antipsychotic medication. Our findings suggest that smoking does not affect the cortisol response in schizophrenic patients as it has been shown in healthy individuals. Future studies should investigate a possible desensitization of the stress system to smoking.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaProgress in Neuro-Psychopharmacology and Biological Psychiatry
Brojčani podacivol. 77, str. 228-235
p-ISSN0278-5846
DOIhttps://doi.org/10.1016/j.pnpbp.2017.04.032
URN:NBNurn:nbn:hr:105:238952
Datum objave publikacije2017-07
URL dokumentahttps://doi.org/10.1016/j.pnpbp.2017.04.032
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 09:17:19